Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Denis

Showing results (291-300 of 310) with videos related to

Pageof 31
Sort By:
Nature Communications|June 20, 2023
The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson's diseaseA de Rus Jacquet, M Alpaugh, H L Denis, et al.
Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)|October 14, 2008
Sialome individuality between Aedes aegypti coloniesL Almeras, E Orlandi-Pradines, A Fontaine, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
Urology|July 22, 1998
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study GroupF J Debruyne, R Murray, Y Fradet, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 3, 2026
Distinct alterations of adiponectin, fibroblast growth factor 21 (FGF-21), and insulin-like growth factor binding protein 2 (IGFBP-2) link dysmetabolism with cognitive decline across the Alzheimer's disease spectrumCaroline Dallaire-Théroux, Helena L Denis, Rosalie Cottez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesM Hidalgo, L L Siu, J Nemunaitis, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 11, 2026
Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohortRosalie J Cottez, Clémence Peyrot, Hélèna L Denis, et al.
The Review of Scientific Instruments|March 2, 2022
SiAl composite feedhorn arrays for astrophysical applications: Cryogenic material propertiesAamir M Ali, Thomas Essinger-Hileman, Tobias Marriage, et al.
Journal of Neurology|March 6, 2025
Tau levels in platelets isolated from Huntington's disease patients serve as a biomarker of disease severityMelanie Alpaugh, Juan Lantero-Rodriguez, Andrea L Benedet, et al.
The British Journal of Dermatology|March 29, 2019
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled studyR Bissonnette, C Maari, S Forman, et al.
Pageof 31

Showing results (291-300 of 310) with videos related to

Sort By:
Pageof 31
Nature Communications|June 20, 2023
The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson's diseaseA de Rus Jacquet, M Alpaugh, H L Denis, et al.
Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)|October 14, 2008
Sialome individuality between Aedes aegypti coloniesL Almeras, E Orlandi-Pradines, A Fontaine, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
Urology|July 22, 1998
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study GroupF J Debruyne, R Murray, Y Fradet, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 3, 2026
Distinct alterations of adiponectin, fibroblast growth factor 21 (FGF-21), and insulin-like growth factor binding protein 2 (IGFBP-2) link dysmetabolism with cognitive decline across the Alzheimer's disease spectrumCaroline Dallaire-Théroux, Helena L Denis, Rosalie Cottez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesM Hidalgo, L L Siu, J Nemunaitis, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 11, 2026
Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohortRosalie J Cottez, Clémence Peyrot, Hélèna L Denis, et al.
The Review of Scientific Instruments|March 2, 2022
SiAl composite feedhorn arrays for astrophysical applications: Cryogenic material propertiesAamir M Ali, Thomas Essinger-Hileman, Tobias Marriage, et al.
Journal of Neurology|March 6, 2025
Tau levels in platelets isolated from Huntington's disease patients serve as a biomarker of disease severityMelanie Alpaugh, Juan Lantero-Rodriguez, Andrea L Benedet, et al.
The British Journal of Dermatology|March 29, 2019
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled studyR Bissonnette, C Maari, S Forman, et al.
Pageof 31